{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "regularMarketChangePercent": 0.0, "regularMarketPrice": 0.34, "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "esgPopulated": false, "exchange": "FRA", "shortName": "REDX PHARMA  LS -,01", "longName": "Redx Pharma Plc", "messageBoardId": "finmb_114713148", "exchangeTimezoneName": "Europe/Berlin", "marketState": "REGULAR", "firstTradeDateMilliseconds": 1611126000000, "priceHint": 4, "regularMarketChange": 0.0, "regularMarketTime": 1683875701, "regularMarketDayHigh": 0.34, "regularMarketDayRange": "0.34 - 0.34", "regularMarketDayLow": 0.34, "regularMarketVolume": 150, "regularMarketPreviousClose": 0.34, "bid": 0.34, "ask": 0.438, "fullExchangeName": "Frankfurt", "financialCurrency": "GBP", "regularMarketOpen": 0.34, "averageDailyVolume3Month": 0, "averageDailyVolume10Day": 0, "fiftyTwoWeekLowChange": 0.03999999, "fiftyTwoWeekLowChangePercent": 0.1333333, "fiftyTwoWeekRange": "0.3 - 0.78", "fiftyTwoWeekHighChange": -0.43999997, "fiftyTwoWeekHighChangePercent": -0.56410253, "fiftyTwoWeekLow": 0.3, "fiftyTwoWeekHigh": 0.78, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.07, "sharesOutstanding": 334911008, "bookValue": 0.099, "fiftyDayAverage": 0.36634, "fiftyDayAverageChange": -0.026340008, "fiftyDayAverageChangePercent": -0.07190044, "twoHundredDayAverage": 0.56846, "twoHundredDayAverageChange": -0.22845998, "twoHundredDayAverageChangePercent": -0.4018928, "marketCap": 123578784, "priceToBook": 3.4343436, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "tradeable": false, "cryptoTradeable": false, "symbol": "0RX.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Alderley Park", "address2": "Block 33 Mereside Alderley Edge", "city": "Macclesfield", "zip": "SK10 4TG", "country": "United Kingdom", "phone": "44 16 2546 9900", "website": "https://www.redxpharma.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating anti-cancer and fibrosis targets in the areas of unmet medical needs. The company also develops RXC004, a porcupine inhibitor that is in Phase II clinical trial for targeted therapy of Wnt-ligand driven cancer; and RXC007, an oral selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor for the treatment of fibrotic diseases. In addition, it develops RXC008, a gastrointestinal targeted ROCK inhibitor to treat crohn's disease-associated fibrosis; discoidin domain receptors (DDRs) inhibitor for the treatment of multiple fibrotic conditions; and RXC006, a porcupine inhibitor targeting fibrotic diseases, including idiopathic pulmonary fibrosis. The company has a research collaboration agreement with Jazz Pharmaceuticals plc to discover and develop drug candidates for two cancer targets in the RAS-RAF-MAP kinase pathway. Redx Pharma Plc was incorporated in 2010 and is based in Macclesfield, the United Kingdom.", "fullTimeEmployees": 95, "companyOfficers": [{"maxAge": 1, "name": "Ms. Lisa Mary Whewell Anson", "age": 52, "title": "CEO & Exec. Director", "yearBorn": 1970, "fiscalYear": 2022, "totalPay": {"raw": 803287, "fmt": "803.29k", "longFmt": "803,287"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 1036914, "fmt": "1.04M", "longFmt": "1,036,914"}}, {"maxAge": 1, "name": "Mr. Peter J. Collum", "title": "Chief Financial Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. James  Mead", "age": 44, "title": "Chief Operating Officer", "yearBorn": 1978, "fiscalYear": 2021, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Richard  Armer", "title": "Chief Scientific Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Karl  Hard Ph.D.", "age": 60, "title": "Head of Investor Relations", "yearBorn": 1962, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Claire  Solk", "title": "Gen. Counsel & Company Sec.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Caitlin  Pearson", "title": "Head of Communications", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Jane  Robertson", "title": "Chief Medical Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Cliff  Jones", "title": "Sr. VP of Chemistry, DMPK & Intellectual Property", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Caroline  Phillips", "title": "Sr. VP of Biology", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}